{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:22:06Z","timestamp":1770816126592,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Given the paucity of evidence-based treatment recommendations, the most appropriate first-line regimen for adult Burkitt lymphoma is currently undefined. We aimed to identify the optimal treatment regimen containing rituximab for adult Burkitt lymphoma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Embase, Web of Science, and Cochrane databases were searched in December 2021 (10). We included all studies for the treatment of Burkitt lymphoma including rituximab. We excluded studies of patients aged \u226414 years old and those with sample numbers \u226410 patients. Random-effects models were used to compare different chemotherapy regimens regarding estimated 2-year overall survival (OS) rate, 2-year progression-free survival (PFS) rate, and overall response rate (ORR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 17 studies were included in this meta-analysis and divided into four groups: CODOX-M\/IVAC, DA-EPOCH, GMALL-B-ALL\/NHL2002, and Hyper-CVAD. DA-EPOCH was associated with a significantly higher 2-year OS rate [0.95, 95% confidence interval (CI) 0.86\u20131.00]. There was no significant difference in the 2-year PFS rates (0.81, 95% CI 0.76\u20130.85) and ORR (0.90, 95% CI 0.87\u20130.94) between these four treatment regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The meta-analysis indicates that DA-EPOCH could be more effective in providing curative treatment for adult Burkitt lymphoma patients, especially without CNS and BM involvement considering OS time. Due to the types of studies and the limited number of included studies, bias should be acknowledged and a randomized controlled trial (RCT) needs to be performed to further identify the optimal treatment regimen for such patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1063689","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:45:12Z","timestamp":1671777912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaoxuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liren","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61177-x","article-title":"Burkitt's lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.24.7837","article-title":"Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human burkitt lymphoma and murine plasmacytoma cells","volume":"79","author":"Taub","year":"1982","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910030619","article-title":"Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus","volume":"3","author":"Pope","year":"1968","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086827","article-title":"High cure rates in burkitt lymphoma and leukemia: A northern Italy leukemia group study of the German short intensive rituximab-chemotherapy program","volume":"98","author":"Intermesoli","year":"2013","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult burkitt Lymphoma\/Leukemia with rituximab and chemotherapy: Report of a Large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-015-2501-1","article-title":"Effect of rituximab on adult burkitt's lymphoma: A systematic review and meta-analysis","volume":"95","author":"Nie","year":"2016","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature b-cell non-hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Internal Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (Minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B12","volume-title":"Joanna Briggs Institute reviewer\u2019s manual","author":"Moola","year":"2017"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000000623","article-title":"Adding rituximab to codox-M\/Ivac chemotherapy in the treatment of hiv-associated burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS (London England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.3","article-title":"Favourable outcomes for high-risk burkitt lymphoma patients (Ipi 3-5) treated with rituximab plus codox-M\/Ivac: Results of a phase 2 uk ncri trial","volume":"1","author":"Phillips","year":"2020","journal-title":"EJHaem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623900","article-title":"Amc 048: Modified codox-M\/Ivac-Rituximab is safe and effective for hiv-associated burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-cvad plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt414","article-title":"A multicenter phase ii study incorporating high-dose rituximab and liposomal doxorubicin into the codox-M\/Ivac regimen for untreated burkitt's lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004427","article-title":"Long-term outcome of hyper-Cvad-R for burkitt Leukemia\/Lymphoma and high-grade b-cell lymphoma: Focus on cns relapse","volume":"5","author":"Samra","year":"2021","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted epoch-r in adults with untreated burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0314","article-title":"Modified r-Codox-M\/Ivac chemotherapy regimens in Chinese patients with untreated sporadic burkitt lymphoma","volume":"18","author":"Chen","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08447.x","article-title":"Rituximab in combination with codox-M\/Ivac: A retrospective analysis of 23 cases of non-hiv related b-cell non-Hodgkin lymphoma with proliferation index >95%","volume":"152","author":"Mohamedbhai","year":"2011","journal-title":"Br J haemato"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.055","article-title":"Treatment outcomes of rituximab plus hyper-cvad in Korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis","volume":"47","author":"Hong","year":"2015","journal-title":"Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"Rd-Codox-M\/Ivac with rituximab and intrathecal liposomal cytarabine in adult burkitt lymphoma and 'Unclassifiable' highly aggressive b-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J haemato"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15262","article-title":"Excellent real-world outcomes of adults with burkitt lymphoma treated with codox-M\/Ivac plus or minus rituximab","volume":"181","author":"Zhu","year":"2018","journal-title":"Br J haemato"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2015.0088","article-title":"The prognosis of adult burkitt\u2019s cell leukemia in real-life clinical practice","volume":"33","author":"Malkan","year":"2016","journal-title":"Turkish J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22047","article-title":"Sporadic childhood burkitt lymphoma incidence in the united states during 1992-2005","volume":"53","author":"Mbulaiteye","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.09.004","article-title":"Gender and age-related differences in burkitt lymphoma\u2013epidemiological and clinical data from the Netherlands","volume":"40","author":"Boerma","year":"2004","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(20)30455-9","article-title":"Burkitt lymphoma - subtypes, pathogenesis, and treatment strategies","author":"Noy","year":"2020","journal-title":"Clin lymphoma myeloma leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in b-cell hematologic malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-Cleaved-Cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"B32","first-page":"LB2370","article-title":"R-CODOX-M\/R-IVAC versus dose-adjusted(DA)-EPOCH-R in patients with newly diagnosed high-risk burkitt lymphoma; first results of a multi-center randomized HOVON\/SAKK trial","author":"Chamuleau","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 us cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03288","article-title":"Burkitt lymphoma international prognostic index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2022.2027402","article-title":"Burkitt lymphoma - no impact of hiv status on outcomes with rituximab-based chemoimmunotherapy","volume":"19","author":"Tan","year":"2022","journal-title":"Leukemia lymphoma"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to codox-M\/Ivac for burkitt's lymphoma: A retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose Methotrexate\/Ifosfamide, etoposide, and high-dose cytarabine (Codox-M\/Ivac) for human immunodeficiency virus-associated burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult burkitt lymphoma: Comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30126-5","article-title":"Hiv-associated burkitt lymphoma","volume":"7","author":"Atallah-Yunes","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1063689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:45:16Z","timestamp":1671777916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1063689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.1063689"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1063689","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"article-number":"1063689"}}